Sarah G. Wallace

Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome

D. Wood, H. Vesselle, J. Bauman, 2019, BMC Cancer.

A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer

J. Bauman, Dennie V. Jones, K. Eaton, 2012, BMC Cancer.

Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.

D. Hayes, N. Futran, E. Mendez, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expression of p16, ERCC1, and EGFR amplification as predictors of responsiveness of locally advanced squamous cell carcinomas of head and neck (SCCHN) to cisplatin, radiotherapy, and erlotinib: A phase II randomized trial.

D. Hayes, B. Kurland, J. Liao, 2012 .

A Phase II study of nab-Paclitaxel (nab-P) in patients with advanced non-small cell lung cancer with EGFR mutations after frontline tyrosine kinase inhibitor therapy.

C. Baik, K. Eaton, Rebecca L. Wood, 2021, Cancer treatment and research communications.